blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2409992

EP2409992 - A HUMAN ANTI-TUMOR NECROSIS FACTOR ALPHA MONOCLONAL ANTIBODY AND USE THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  31.08.2018
Database last updated on 28.05.2024
FormerThe patent has been granted
Status updated on  22.09.2017
FormerGrant of patent is intended
Status updated on  15.09.2017
FormerExamination is in progress
Status updated on  25.07.2017
FormerGrant of patent is intended
Status updated on  05.04.2017
FormerExamination is in progress
Status updated on  04.01.2017
Most recent event   Tooltip26.06.2020Lapse of the patent in a contracting state
New state(s): MK		published on 29.07.2020  [2020/31]
Applicant(s)For all designated states
Danyang Zhengyuan Biotech Co. Ltd.
Industrial Park for Overseas Chinese Students
Bawei Rd.
Danyang Economic Development Zone
Danyang City
Jiangsu 212300 / CN
[2012/08]
Former [2012/04]For all designated states
Shanghai Programmed Artificial Evolution Co., Ltd.
Room 2620 Building No.3 277 Zheqiao Road Pu Dong District
Shanghai 201206 / CN
Inventor(s)01 / LIU, Qingfa
Room 304, Tower 2
No.720 Cailun Rd.
PU Dong
Shanghai 201203 / CN
 [2012/04]
Representative(s)Kador & Partner Part mbB
Corneliusstraße 15
80469 München / DE
[N/P]
Former [2017/43]Kador & Partner
Corneliusstraße 15
80469 München / DE
Former [2012/04]Kador & Partner
Corneliusstrasse 15
80469 München / DE
Application number, filing date09841729.820.03.2009
[2017/43]
WO2009CN70938
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2010105446
Date:23.09.2010
Language:ZH
[2010/38]
Type: A1 Application with search report 
No.:EP2409992
Date:25.01.2012
Language:EN
[2012/04]
Type: B1 Patent specification 
No.:EP2409992
Date:25.10.2017
Language:EN
[2017/43]
Search report(s)International search report - published on:CN23.09.2010
(Supplementary) European search report - dispatched on:EP06.07.2012
ClassificationIPC:C07K16/24, C12N15/13, A61K39/395, A61P19/02, A61P29/00, C07K14/71
[2012/32]
CPC:
C07K16/241 (EP,US); A61P19/02 (EP); A61P29/00 (EP);
C07K14/71 (EP,US); A61K2039/505 (EP,US); C07K2317/21 (EP,US);
C07K2317/52 (EP,US); C07K2317/55 (EP,US); C07K2317/76 (EP,US);
C07K2319/00 (EP,US) (-)
Former IPC [2012/04]C07K16/24, C12N15/13, A61K39/395, A61P19/02, A61P29/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2012/04]
Extension statesALNot yet paid
BANot yet paid
RSNot yet paid
TitleGerman:HUMANER, MONOKLONALER ANTI-TUMORNEKROSEFAKTOR-ALPHA-ANTIKÖRPER UND ANWENDUNG DAVON[2012/04]
English:A HUMAN ANTI-TUMOR NECROSIS FACTOR ALPHA MONOCLONAL ANTIBODY AND USE THEREOF[2012/04]
French:ANTICORPS MONOCLONAL ANTI-FACTEUR DE NÉCROSE TUMORALE ALPHA HUMAIN ET SON UTILISATION[2012/04]
Entry into regional phase08.09.2011Translation filed 
08.09.2011National basic fee paid 
08.09.2011Search fee paid 
08.09.2011Designation fee(s) paid 
08.09.2011Examination fee paid 
Examination procedure08.09.2011Examination requested  [2012/04]
21.01.2013Amendment by applicant (claims and/or description)
08.03.2016Despatch of a communication from the examining division (Time limit: M04)
13.07.2016Reply to a communication from the examining division
02.09.2016Despatch of a communication from the examining division (Time limit: M04)
21.12.2016Reply to a communication from the examining division
06.04.2017Communication of intention to grant the patent
20.06.2017Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
20.06.2017Fee for grant paid
20.06.2017Fee for publishing/printing paid
15.09.2017Information about intention to grant a patent
15.09.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  08.03.2016
Opposition(s)26.07.2018No opposition filed within time limit [2018/40]
Fees paidRenewal fee
29.09.2011Renewal fee patent year 03
28.03.2012Renewal fee patent year 04
28.01.2013Renewal fee patent year 05
26.02.2014Renewal fee patent year 06
27.03.2015Renewal fee patent year 07
23.03.2016Renewal fee patent year 08
16.03.2017Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU20.03.2009
AT25.10.2017
CY25.10.2017
CZ25.10.2017
DK25.10.2017
EE25.10.2017
ES25.10.2017
FI25.10.2017
HR25.10.2017
IT25.10.2017
LT25.10.2017
LV25.10.2017
MC25.10.2017
MK25.10.2017
NL25.10.2017
PL25.10.2017
PT25.10.2017
RO25.10.2017
SE25.10.2017
SI25.10.2017
SK25.10.2017
TR25.10.2017
BG25.01.2018
NO25.01.2018
GR26.01.2018
IS25.02.2018
GB20.03.2018
IE20.03.2018
LU20.03.2018
MT20.03.2018
BE31.03.2018
CH31.03.2018
FR31.03.2018
LI31.03.2018
[2020/31]
Former [2020/27]HU20.03.2009
AT25.10.2017
CY25.10.2017
CZ25.10.2017
DK25.10.2017
EE25.10.2017
ES25.10.2017
FI25.10.2017
HR25.10.2017
IT25.10.2017
LT25.10.2017
LV25.10.2017
MC25.10.2017
NL25.10.2017
PL25.10.2017
PT25.10.2017
RO25.10.2017
SE25.10.2017
SI25.10.2017
SK25.10.2017
TR25.10.2017
BG25.01.2018
NO25.01.2018
GR26.01.2018
IS25.02.2018
GB20.03.2018
IE20.03.2018
LU20.03.2018
MT20.03.2018
BE31.03.2018
CH31.03.2018
FR31.03.2018
LI31.03.2018
Former [2020/16]AT25.10.2017
CY25.10.2017
CZ25.10.2017
DK25.10.2017
EE25.10.2017
ES25.10.2017
FI25.10.2017
HR25.10.2017
IT25.10.2017
LT25.10.2017
LV25.10.2017
MC25.10.2017
NL25.10.2017
PL25.10.2017
RO25.10.2017
SE25.10.2017
SI25.10.2017
SK25.10.2017
TR25.10.2017
BG25.01.2018
NO25.01.2018
GR26.01.2018
IS25.02.2018
GB20.03.2018
IE20.03.2018
LU20.03.2018
MT20.03.2018
BE31.03.2018
CH31.03.2018
FR31.03.2018
LI31.03.2018
Former [2020/08]AT25.10.2017
CY25.10.2017
CZ25.10.2017
DK25.10.2017
EE25.10.2017
ES25.10.2017
FI25.10.2017
HR25.10.2017
IT25.10.2017
LT25.10.2017
LV25.10.2017
MC25.10.2017
NL25.10.2017
PL25.10.2017
RO25.10.2017
SE25.10.2017
SI25.10.2017
SK25.10.2017
BG25.01.2018
NO25.01.2018
GR26.01.2018
IS25.02.2018
GB20.03.2018
IE20.03.2018
LU20.03.2018
MT20.03.2018
BE31.03.2018
CH31.03.2018
FR31.03.2018
LI31.03.2018
Former [2019/23]AT25.10.2017
CY25.10.2017
CZ25.10.2017
DK25.10.2017
EE25.10.2017
ES25.10.2017
FI25.10.2017
HR25.10.2017
IT25.10.2017
LT25.10.2017
LV25.10.2017
MC25.10.2017
NL25.10.2017
PL25.10.2017
RO25.10.2017
SE25.10.2017
SI25.10.2017
SK25.10.2017
BG25.01.2018
NO25.01.2018
GR26.01.2018
IS25.02.2018
GB20.03.2018
IE20.03.2018
LU20.03.2018
BE31.03.2018
CH31.03.2018
FR31.03.2018
LI31.03.2018
Former [2019/12]AT25.10.2017
CY25.10.2017
CZ25.10.2017
DK25.10.2017
EE25.10.2017
ES25.10.2017
FI25.10.2017
HR25.10.2017
IT25.10.2017
LT25.10.2017
LV25.10.2017
MC25.10.2017
NL25.10.2017
PL25.10.2017
RO25.10.2017
SE25.10.2017
SI25.10.2017
SK25.10.2017
BG25.01.2018
NO25.01.2018
GR26.01.2018
IS25.02.2018
GB20.03.2018
IE20.03.2018
LU20.03.2018
BE31.03.2018
CH31.03.2018
LI31.03.2018
Former [2019/09]AT25.10.2017
CY25.10.2017
CZ25.10.2017
DK25.10.2017
EE25.10.2017
ES25.10.2017
FI25.10.2017
HR25.10.2017
IT25.10.2017
LT25.10.2017
LV25.10.2017
MC25.10.2017
NL25.10.2017
PL25.10.2017
RO25.10.2017
SE25.10.2017
SI25.10.2017
SK25.10.2017
BG25.01.2018
NO25.01.2018
GR26.01.2018
IS25.02.2018
IE20.03.2018
LU20.03.2018
Former [2019/04]AT25.10.2017
CY25.10.2017
CZ25.10.2017
DK25.10.2017
EE25.10.2017
ES25.10.2017
FI25.10.2017
HR25.10.2017
IT25.10.2017
LT25.10.2017
LV25.10.2017
MC25.10.2017
NL25.10.2017
PL25.10.2017
RO25.10.2017
SE25.10.2017
SI25.10.2017
SK25.10.2017
BG25.01.2018
NO25.01.2018
GR26.01.2018
IS25.02.2018
LU20.03.2018
Former [2018/52]AT25.10.2017
CY25.10.2017
CZ25.10.2017
DK25.10.2017
EE25.10.2017
ES25.10.2017
FI25.10.2017
HR25.10.2017
IT25.10.2017
LT25.10.2017
LV25.10.2017
MC25.10.2017
NL25.10.2017
PL25.10.2017
RO25.10.2017
SE25.10.2017
SI25.10.2017
SK25.10.2017
BG25.01.2018
NO25.01.2018
GR26.01.2018
IS25.02.2018
Former [2018/41]AT25.10.2017
CY25.10.2017
CZ25.10.2017
DK25.10.2017
EE25.10.2017
ES25.10.2017
FI25.10.2017
HR25.10.2017
IT25.10.2017
LT25.10.2017
LV25.10.2017
NL25.10.2017
PL25.10.2017
RO25.10.2017
SE25.10.2017
SK25.10.2017
BG25.01.2018
NO25.01.2018
GR26.01.2018
IS25.02.2018
Former [2018/39]AT25.10.2017
CY25.10.2017
CZ25.10.2017
DK25.10.2017
EE25.10.2017
ES25.10.2017
FI25.10.2017
HR25.10.2017
IT25.10.2017
LT25.10.2017
LV25.10.2017
NL25.10.2017
PL25.10.2017
SE25.10.2017
SK25.10.2017
BG25.01.2018
NO25.01.2018
GR26.01.2018
IS25.02.2018
Former [2018/37]AT25.10.2017
CY25.10.2017
CZ25.10.2017
DK25.10.2017
EE25.10.2017
ES25.10.2017
FI25.10.2017
HR25.10.2017
LT25.10.2017
LV25.10.2017
NL25.10.2017
PL25.10.2017
SE25.10.2017
SK25.10.2017
BG25.01.2018
NO25.01.2018
GR26.01.2018
IS25.02.2018
Former [2018/35]AT25.10.2017
CY25.10.2017
CZ25.10.2017
DK25.10.2017
EE25.10.2017
ES25.10.2017
FI25.10.2017
HR25.10.2017
LT25.10.2017
LV25.10.2017
NL25.10.2017
SE25.10.2017
SK25.10.2017
BG25.01.2018
NO25.01.2018
GR26.01.2018
IS25.02.2018
Former [2018/24]AT25.10.2017
ES25.10.2017
FI25.10.2017
HR25.10.2017
LT25.10.2017
LV25.10.2017
NL25.10.2017
SE25.10.2017
BG25.01.2018
NO25.01.2018
GR26.01.2018
IS25.02.2018
Former [2018/23]AT25.10.2017
ES25.10.2017
FI25.10.2017
HR25.10.2017
LT25.10.2017
NL25.10.2017
SE25.10.2017
NO25.01.2018
GR26.01.2018
IS25.02.2018
Former [2018/22]ES25.10.2017
FI25.10.2017
LT25.10.2017
NL25.10.2017
NO25.01.2018
Former [2018/21]FI25.10.2017
LT25.10.2017
NL25.10.2017
NO25.01.2018
Former [2018/17]NL25.10.2017
Documents cited:Search[A]US6090382  (SALFELD JOCHEN G [US], et al) [A] 1-8 * example - ** claim - *;
 [I]WO2006014477  (BIOREN INC [US], et al) [I] 1-8 * tables 2,6 *;
 [I]  - A. RAJPAL ET AL., "A general method for greatly improving the affinity of antibodies by using combinatorial libraries.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE U.S.A., Washington DC, USA, (20050614), vol. 102, no. 24, pages 8466 - 8471, XP002347095 [I] 1-8 * abstract * * table 3 * * figure 4 *

DOI:   http://dx.doi.org/10.1073/pnas.0503543102
International search[A]CN1613874  (ZHONGXIN GUOJIAN PHARMACEUTICA [CN]);
 [A]CN1745101  (ABGENIX INC [US]);
 [A]CN1778921  (NO 4 MILITARY MEDICAL UNIV OF [CN]);
 [A]WO2006071091  (YUHAN CORP [KR], et al);
 [A]CN1882611  (YUHAN CORP [KR]);
 [A]WO2008141511  (HUMAN ANTIBODOMICS SHANGHAI IN [CN], et al)
by applicant   - JOURNAL OF IMMUNOLOGICAL METHODS, (2005), vol. 298, pages 9 - 20
    - MARKS ET AL., "By-passing immunization: human antibodies from V-gene libraries displayed on phage", J MOL. BIOL., vol. 222, doi:doi:10.1016/0022-2836(91)90498-U, pages 581 - 597, XP024010124

DOI:   http://dx.doi.org/10.1016/0022-2836(91)90498-U
    - HOOGENBOOM, WINTER, "By-passing immunisation: human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro", J MOL. BIOL., vol. 227, doi:doi:10.1016/0022-2836(92)90894-P, pages 381 - 388, XP024020530

DOI:   http://dx.doi.org/10.1016/0022-2836(92)90894-P
    - HAIDARIS CG, MALONE J, SHERRILL LA, BLISS JM, GASPARI AA, INSEL RA, SULLIVAN MA., "Recombinant human antibody single chain variable fragments reactive with Candida albicans surface antigens", J IMMUNOL METHODS, (2001), vol. 257, no. 1-2, doi:doi:10.1016/S0022-1759(01)00463-X, pages 185 - 202, XP004311950

DOI:   http://dx.doi.org/10.1016/S0022-1759(01)00463-X
    - GRIFFITHS, A. D., WILLIAMS, S. C., HARTLEY, O., TOMLINSON, 1. M., WATERHOUSE, P., CROSBY, W. L., KONTERMANN, R. E, JONES, P. T., L, "Isolation of high affinity human antibodies directly from large synthetic repertoires", EMBO J, (1994), vol. 13, pages 3245 - 3260
    - NISSIM, A., HOOGENBOOM, H. R., TOMLINSON, I. M., FLYNN, G., MIDGLEY, C., LANE, D., WINTER, G., "Antibody fragments from a 'single pot' phage display library as immunochemical reagents", EMBO J., (1994), vol. 13, pages 692 - 698
    - MUNSON ET AL., ANAL. BIOCHEM., (1980), vol. 107, page 220
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.